Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.



From the monthly archives: December, 2019

We are pleased to present below all posts archived in 'December, 2019'. If you still can't find what you are looking for, try using the search box.

Understanding the 3D shape of Oligodendrocytes

AMSBIO reports on the pioneering research published** by scientists at Stanford University Medical School that has cited Mimetix® aligned 3D cell culture scaffold supplied by the company to understand the architecture of the myelin sheaths which insulate neuronal axons, so they can transmit electrical impulses quickly and efficiently.
 

Read the rest of entry »

Pathios Therapeutics closes US$8.8M Series A and appoints Stuart Hughes as CEO

OXFORD, UK 18th DECEMBER 2019: Pathios Therapeutics Limited (“Pathios”), an innovative biotech company focused on the development of first-in-class therapies for autoimmune diseases and cancer, today announced a US$8.8M Series A financing round with leading international healthcare investors Canaan and Australia’s Medical Research Commercialisation Fund managed by Brandon Capital (“MRCF”). 

Read the rest of entry »

Arctoris Ltd Successfully Moves into its New Global Headquarters in Oxford, UK

OXFORD, UK – 11th December 2019 – Arctoris Ltd, the developer of the world’s first fully automated drug discovery platform, today opened the doors to its new global headquarters and state-of-the-art research and development (R&D) facility in Oxford, UK. Housing the company’s proprietary technology and providing space for its rapidly growing commercial and scientific teams, the facility will enable Arctoris to continue to support its research partners around the world with its structured, automated approach to drug discovery.

Read the rest of entry »

AMSBIO: 3D Cell Culture Proves Invaluable to Myelination Research

AMSBIO reports on the pioneering research published** by scientists at Stanford University Medical School that has cited Mimetix® aligned 3D cell culture scaffold supplied by the company to understand the architecture of the myelin sheaths which insulate neuronal axons, so they can transmit electrical impulses quickly and efficiently.

Read the rest of entry »

Upperton is Launching an Enabling Technology Screening Protocol

Upperton Pharma Solutions, a UK-based contract development and manufacturing organisation (CDMO) are launching a platform which aims to support companies with the rapid development of both standard and complex drug products.

Read the rest of entry »

The Oxford Science Park: Green light for planning permission at Plot 16 as The Oxford Science Park continues ambitious expansion plans 

Oxford, UK, December 5 2019 - Oxford City Council’s East Area Planning Committee has approved the detailed plans for two office / laboratory buildings on The Oxford Science Park’s Plot 16 comprising 168,000 sq ft (15,600 sq m).  The plans feature a central raised plaza and wider landscaping and accessibility enhancements. 

Read the rest of entry »

Arecor announces positive headline results for the first Phase I clinical trial of AT247, a novel ultra rapid acting formulation of insulin

Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247.  In the study, AT247 provided a favourable pharmacokinetic/pharmacodynamic profile compared with NovoRapid® and Fiasp®.

Read the rest of entry »

UK-Based Absolute Antibody Partners with the Recombinant Antibody Network

Redcar, UK, December 3, 2019. Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced a partnership with the Recombinant Antibody Network (RAN), a consortium of three expert centers at the University of Chicago, University of Toronto, and UC San Francisco (UCSF) with a common goal to generate recombinant antibodies at a proteome-wide scale.

Read the rest of entry »

Data Magik launches our latest version of clinical trial system “Kapture”

Data Magik is proud to announce the launch of our latest version of clinical trial system “Kapture” and brand new website (www.datakapture.co.uk).

Read the rest of entry »

Aptus Clinical selected as clinical CRO by artelo biosciences

Aptus Clinical has been appointed full service clinical CRO partner by Artelo Biosciences Inc. (through their fully owned UK subsidiary, Trinity R&D Ltd). to deliver the upcoming Phase 1B/2A trial of their synthetic cannabinoid, ART27.13. This latest agreement builds on an earlier research and development partnership agreement, where Aptus successfully designed and supported the critical path pre-clinical experiments and completed key clinical strategy and planning activities for Artelo.

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.